Royalty Pharma Locks in $100M Zealand Pharma Funding Pact for Blood Disorder Drug

기사 요약

Royalty Pharma will pay Zealand Pharma $100 million for economic rights tied to rusfertide, with FDA action expected in Q3 of 2026.